BeiGene
BGNE
#964
Rank
S$27.16 B
Marketcap
$248.33
Share price
0.49%
Change (1 day)
15.72%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -$22.80

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -$22.37. In 2022 the company made an earnings per share (EPS) of -$26.04 a decrease over its 2021 EPS that were of -$20.45.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$22.80-12.43%
2022-$26.0427.35%
2021-$20.45-19.96%
2020-$25.5520.81%
2019-$21.1531.52%
2018-$16.08417.57%
2017-$3.11-37.16%
2016-$4.94158.95%
2015-$1.91

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$1.34-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.36-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA